Joseph J Wolk Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 4 months, 2 weeks ago
Joseph J Wolk has an estimated net worth of at least $23.0 million*, as of Oct. 1, 2025. They own 82,835 shares of JNJ stock. They have sold 44,616 shares of JNJ stock since 2021, for an estimated $7.6 million.
Joseph J Wolk $JNJ SEC Form 4 Insider Trading
Joseph J Wolk has filed a total of 4 insider trades in $JNJ since 2021. Their most recent trade was a sale of 16,820 shares, made on Aug 15, 2025. Their largest trade was a sale of 16,820 shares, made on Aug 15, 2025. We estimate that they now own 82,835 shares of $JNJ, worth an estimated $15.3 million.
Insider Trading at $JNJ
There have been a total of 358 insider trades reported at $JNJ since 2021, with 2,250 shares purchased and 997,448 shares sold. The most active insider traders in $JNJ stock have been Peter Fasolo, Thibaut Mongon, and William Hait. The most recent trade was a sale of 48,782 shares reported by Joaquin Duato (CEO and Chairman of the Board), made on Jan 26, 2026.
History of Insider Stock Trades by Joseph J Wolk
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
PRU
|
Purchase | 400 | Feb 11, 2026 | Feb. 12, 2026, 10:44 a.m. |
JNJ
|
Sale | 16,820 | Aug 15, 2025 | Aug. 18, 2025, 6:19 p.m. |
|
JNJ
|
Sale | 13,015 | Feb 07, 2025 | Feb. 11, 2025, 8:40 p.m. |
|
JNJ
|
Sale | 1,855 | Dec 13, 2022 | Dec. 15, 2022, 5:34 p.m. |
|
JNJ
|
Sale | 12,926 | Dec 13, 2022 | Dec. 15, 2022, 5:34 p.m. |
$JNJ Executives and Stock Owners with Insider Trades
-
Peter Fasolo, Exec VP, Chief HR Officer
-
Thibaut Mongon, Exec VP, WW Chair, Consumer
-
William Hait, See Remarks
-
Kathryn E Wengel, EVP, Chief GSC Officer
-
Joseph J Wolk, Exec VP, CFO
-
Joaquin Duato, CEO and Chairman of the Board
-
Robert J Decker, Controller, CAO
-
Ashley Mcevoy, EVP, WW Chair, MedTech
-
John C Reed, EVP, Innovative Medicine, R&D
-
Jennifer L Taubert, EVP, WW Chair, Pharmaceuticals
-
Robert J Decker, VP Corporate Controller
-
James D. Swanson, See Remarks
-
Jennifer L Taubert, EVP, WWC. Innovative Medicine
-
Kathryn E Wengel, EVP, Chief TO and Risk Officer
-
Timothy Schmid, EVP, WW Chair, MedTech
-
Vanessa Broadhurst, EVP, Global Corp Affairs
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.